Actuate Therapeutics to Showcase AI-Driven Drug Development in Lantern Pharma Webinar

AI-Driven Collaboration in Cancer Drug Development

Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced its participation in a webinar hosted by Lantern Pharma on October 30, 2024. The webinar will focus on the application of artificial intelligence in drug development, specifically for cancer treatments 1

1

2

Key Participants and Focus

The webinar will feature Andrew Mazar, Ph.D., Chief Operating Officer of Actuate Therapeutics, and Joseph McDermott, Ph.D., Lantern's computational biologist. They will discuss the ongoing multi-year research and development collaboration between the two companies, which aims to accelerate the development of Actuate's lead drug candidate, elraglusib 1

1

2

Elraglusib: A Novel Cancer Treatment Approach

Elraglusib is a novel GSK-3β inhibitor currently under evaluation in clinical trials:

1. Phase 2 Trial for metastatic pancreatic cancer (NCT03678883)
2. Phase 1/2 Trial for Ewing Sarcoma (EWS) and EWS-related sarcomas (NCT04239092)

The drug targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments. It also acts as a mediator of anti-tumor immunity through the inhibition of NF-kB in immune cells and regulates multiple immune checkpoints 1

1

2

AI's Role in Biomarker Identification

A key aspect of the collaboration is the use of Lantern's AI platform for identifying and developing enrichment biomarkers for elraglusib. This AI-driven approach enables:

1. Screening for additional biomarkers
2. Assessing and predicting therapeutic activity
3. Forecasting clinical outcomes

The integration of AI in this process represents a significant step forward in personalized medicine and targeted cancer therapies 1

1

2

Related Stories

Mainz Biomed Partners with Liquid Biosciences to Enhance Pancreatic Cancer Detection Using AI

Breakthrough Oncology Research Fuels Multibillion-Dollar Opportunities in Cancer Therapies

Gain Therapeutics Reports Q2 2024 Financial Results and Provides Corporate Update

Adagene's ADG126 Shows Promising Results in Combination with Keytruda at ESMO Congress

Actuate Therapeutics: Company Overview

Actuate Therapeutics focuses on developing treatments for high-impact, difficult-to-treat cancers. Their approach centers on the inhibition of glycogen synthase kinase-3 beta (GSK-3β). Elraglusib, their lead investigational drug, targets various molecular pathways in cancer, including:

1. EMT (Epithelial-Mesenchymal Transition)
2. NF-kB-mediated resistance
3. Several DDR (DNA Damage Response) pathways 1

   1

   2

   2

Implications and Future Prospects

This collaboration between Actuate Therapeutics and Lantern Pharma exemplifies the growing trend of AI integration in pharmaceutical research. By leveraging AI for biomarker identification and drug development, the companies aim to:

1. Accelerate the drug development process
2. Enhance the precision of cancer treatments
3. Potentially improve clinical outcomes for patients with difficult-to-treat cancers

However, as with all drug development processes, the companies caution that there are risks and uncertainties involved, including the potential for unfavorable clinical trial results or regulatory hurdles 1

1

2